International Journal of Contemporary Pediatrics,
Journal Year:
2023,
Volume and Issue:
10(12), P. 1876 - 1880
Published: Nov. 4, 2023
Atopic
dermatitis
is
a
prominent
dermatological
condition
in
children
that
frequently
affects
their
lifestyle.
Conventional
treatments
prove
inadequate,
necessitating
the
use
of
biological
agents
like
Lebrikizumab
to
address
at
its
core
pathophysiological
level.
The
introduction
biologic
drugs
has
broadened
spectrum
treatment
options
for
patients
with
moderate
severe
atopic
dermatitis,
especially
those
who
have
not
achieved
satisfactory
results
conventional
monotherapy
or
combination
therapies,
contraindications
systemic
immunosuppressive
agents.
appears
be
promising
option
showing
strong
response
clinical
trials.
It
offers
potential
improved
long-term
efficacy
and
reduction
adverse
effects.
This
article
provides
an
overview
Lebrikizumab's
role
addressing
pathogenesis
highlights
current
advancements.
Dermatological Reviews,
Journal Year:
2025,
Volume and Issue:
6(2)
Published: March 24, 2025
ABSTRACT
Aim
This
study
aims
to
provide
a
comprehensive
analysis
of
keratinocytes,
the
predominant
cell
type
in
epidermis,
by
examining
their
structural,
functional,
and
regulatory
roles
skin
biology.
The
explores
intricate
processes
keratinocyte
differentiation,
proliferation,
immune
interactions,
emphasizing
essential
contributions
homeostasis,
wound
healing,
barrier
integrity.
Additionally,
it
investigates
involvement
keratinocytes
dermatological
disorders
such
as
psoriasis,
atopic
dermatitis,
cancer,
highlighting
pathological
alterations
molecular
mechanisms.
Methods
review
covers
broad
range
studies,
including
vitro
vivo
research
on
biology,
interactions
with
growth
factors,
inflammatory
responses
skin.
It
also
discusses
therapeutic
advancements
biologics
gene
therapy
that
focus
restoring
function
diseases.
Results
highlights
play
pivotal
role
inflammation
regulation
factors
promote
healing
regeneration.
Dysregulation
is
linked
several
diseases,
need
for
targeted
approaches.
Recent
treatments,
biologics,
offer
promising
outcomes
managing
conditions
driven
dysfunction.
Conclusion
primary
aim
this
an
in‐depth
overview
functions
particularly
health,
inflammation,
disease
development.
highlight
latest
strategies
targeting
treatment
Biomedicines,
Journal Year:
2024,
Volume and Issue:
12(8), P. 1841 - 1841
Published: Aug. 13, 2024
Atopic
dermatitis
is
a
chronic
inflammatory
dermatosis
characterized
by
pruritic,
scaly,
erythematous
lesions.
Its
incidence
varies
but
estimated
to
be
approximately
20%
in
children
and
between
7
14%
adults,
with
variation
amongst
countries.
It
multifactorial
condition,
complex
interplay
genetic,
immunological,
environmental
factors.
Research
into
the
response
has
identified
new
therapeutic
targets
that
work
reduce
inflammation
subsequently
flares.
This
study
explores
existing
agents
for
atopic
as
well
newer
therapies
such
biologics
small
molecules,
drawing
upon
each
agent's
mechanism
of
action,
relevant
landmark
clinical
trials,
efficacy,
safety
profile.
Current
include
emollients,
corticosteroids,
cyclosporine
A,
calcineurin
inhibitors,
phototherapy,
methotrexate.
Biologics
described
dupilumab,
tralokinumab,
lebrikizumab,
nemolizumab,
rocatinlimab.
Small
molecules
inhibitors
Janus
kinase
phosphodiesterase
4
transient
receptor
potential
vanilloid
subfamily
V
member
1
antagonist,
aryl
hydrocarbon
antagonist.
Cells,
Journal Year:
2024,
Volume and Issue:
13(16), P. 1398 - 1398
Published: Aug. 22, 2024
Atopic
dermatitis
(AD)
is
a
prevalent
and
chronic
inflammatory
skin
condition
characterized
by
multifaceted
pathophysiology
that
gives
rise
to
diverse
clinical
manifestations.
The
management
of
AD
remains
challenging
due
the
suboptimal
efficacy
existing
treatment
options.
Nonetheless,
recent
progress
in
elucidating
underlying
mechanisms
disease
has
facilitated
identification
new
potential
therapeutic
targets
promising
drug
candidates.
In
this
review,
we
summarize
newest
data,
considering
multiple
connections
between
IL-22
AD.
presence
circulating
been
found
correlate
with
severity
identified
as
critical
factor
driving
response
associated
condition.
Elevated
levels
patients
are
correlated
increased
proliferation
keratinocytes,
alterations
microbiota,
impaired
epidermal
barrier
function.
Collectively,
these
factors
contribute
manifestation
characteristic
symptoms
observed
Journal of Clinical Medicine,
Journal Year:
2022,
Volume and Issue:
11(19), P. 5633 - 5633
Published: Sept. 24, 2022
Atopic
dermatitis
(AD)
is
a
common
inflammatory
skin
disease
with
complex
pathophysiology,
intertwining
immune
dysregulation,
epidermal
barrier
dysfunction,
IgE
sensitization,
environmental
factors
and
genetic
predisposition.
It
has
been
recently
identified
that
interleukins
-4
-13
play
crucial
roles
in
the
type-2-driven
inflammation
characterizes
AD,
contributing
to
its
symptomatology.
Novel
therapeutic
approaches
target
Th2
cytokines
their
respective
pathways
have
developed,
aiming
optimize
treatment
of
AD.
Balkan Medical Journal,
Journal Year:
2024,
Volume and Issue:
unknown, P. 239 - 247
Published: July 5, 2024
Atopic
dermatitis
(AD)
is
a
chronic
inflammatory
condition
that
significantly
affects
the
quality
of
life
both
patients
and
their
families
or
caregivers.
Recently,
treatment
for
moderate-to-severe
AD
were
limited
to
conventional
immunosuppressive
therapies.
However,
currently,
with
approval
biologic
treatments
oral
small
molecules
in
past
decade,
effective
safe
management
possible.
Despite
these
advancements,
challenges
unmet
needs
clinical
practice
remain.
This
includes
who
do
not
respond
well
cannot
tolerate
existing
options
inadequate
therapies
can
modify
disease
course.
review
aimed
provide
an
overview
current
approach
AD,
highlight
treatment,
discuss
rationale
novel
emerging
evidence
on
systemic
AD.
Dermatitis,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 18, 2025
Background:
The
data
are
limited
on
the
real-world
effectiveness
of
an
anti-interleukin
(IL)-13
monoclonal
antibody
lebrikizumab
for
atopic
dermatitis
(AD).
Objective:
To
evaluate
24-week
in
Japanese
patients
with
AD,
stratified
by
presence
or
absence
prior
systemic
therapy.
Methods:
We
conducted
a
multicenter,
prospective
study
134
AD
treated
lebrikizumab.
evaluated
clinical
outcomes
throughout
period
without
Results:
Among
lebrikizumab-treated
patients,
eczema
area
and
severity
index
(EASI)
scores
patient-reported
(peak
pruritus
numerical
rating
scale,
sleep
quality
control
tool,
dermatology
life
index,
patient-oriented
measure)
rapidly
decreased
until
week
12,
these
improvements
persisted
24.
At
24,
achievement
rates
EASI
75,
90,
investigator's
global
assessment
0/1
therapy-naïve
were
75.6%,
58.5%,
43.5%,
respectively,
which
higher
than
those
therapy-experienced
55.5%,
22.2%,
26.9%,
respectively.
There
no
serious
treatment-emergent
adverse
events
Conclusion:
Lebrikizumab
treatment
provided
favorable
tolerability
practice,
slightly
compared
to
patients.
Journal of Clinical Medicine,
Journal Year:
2023,
Volume and Issue:
12(6), P. 2091 - 2091
Published: March 7, 2023
Atopic
dermatitis
(AD)
is
a
common
highly
pruritic
chronic
inflammatory
skin
disorder
affecting
5–20%
of
children
worldwide,
while
the
prevalence
in
adults
varies
from
7
to
10%.
Patients
with
AD
experience
intense
pruritus
that
could
lead
sleep
disturbance
and
impaired
quality
life.
Here,
we
analyze
pathophysiology
itchiness
AD.
We
extensively
review
histamine-dependent
histamine-independent
pruritogens.
Several
receptors,
substance
P,
secreted
molecules,
chemokines,
cytokines
are
involved
as
mediators
itch.
also,
summarize
new
emerging
antipruritic
drugs
atopic
dermatitis.
The Annual Review of Pharmacology and Toxicology,
Journal Year:
2023,
Volume and Issue:
64(1), P. 481 - 506
Published: Sept. 19, 2023
The
exponential
rise
in
the
prevalence
of
allergic
diseases
since
mid-twentieth
century
has
led
to
a
genuine
public
health
emergency
and
also
fostered
major
progress
research
on
underlying
mechanisms
potential
treatments.
management
benefits
from
biological
revolution,
with
an
array
novel
immunomodulatory
therapeutic
investigational
tools
targeting
players
inflammation
at
distinct
pathophysiological
steps.
Prominent
examples
include
monoclonal
antibodies
against
cytokines,
alarmins,
their
receptors,
as
well
small-molecule
modifiers
signal
transduction
mainly
mediated
by
Janus
kinases
Bruton's
tyrosine
kinases.
However,
first-line
options
have
yet
switch
symptomatic
disease-modifying
interventions.
Here
we
present
overview
available
drugs
context
our
current
understanding
allergy
pathophysiology,
identify
targets,
conclude
providing
selection
candidate
immunopharmacological
molecules
under
investigation
for
future
use
diseases.
